These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

177 related articles for article (PubMed ID: 22741039)

  • 1. Hypoxia Moderates γ(1)34.5-Deleted Herpes Simplex Virus Oncolytic Activity in Human Glioma Xenoline Primary Cultures.
    Friedman GK; Haas MC; Kelly VM; Markert JM; Gillespie GY; Cassady KA
    Transl Oncol; 2012 Jun; 5(3):200-7. PubMed ID: 22741039
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Engineered herpes simplex viruses efficiently infect and kill CD133+ human glioma xenograft cells that express CD111.
    Friedman GK; Langford CP; Coleman JM; Cassady KA; Parker JN; Markert JM; Yancey Gillespie G
    J Neurooncol; 2009 Nov; 95(2):199-209. PubMed ID: 19521665
    [TBL] [Abstract][Full Text] [Related]  

  • 3. γ₁34.5-deleted HSV-1-expressing human cytomegalovirus IRS1 gene kills human glioblastoma cells as efficiently as wild-type HSV-1 in normoxia or hypoxia.
    Friedman GK; Nan L; Haas MC; Kelly VM; Moore BP; Langford CP; Xu H; Han X; Beierle EA; Markert JM; Cassady KA; Gillespie GY
    Gene Ther; 2015 Apr; 22(4):348-55. PubMed ID: 25427614
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Oncolytic herpes simplex virus counteracts the hypoxia-induced modulation of glioblastoma stem-like cells.
    Sgubin D; Wakimoto H; Kanai R; Rabkin SD; Martuza RL
    Stem Cells Transl Med; 2012 Apr; 1(4):322-32. PubMed ID: 23197811
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Human glioblastoma-derived cancer stem cells: establishment of invasive glioma models and treatment with oncolytic herpes simplex virus vectors.
    Wakimoto H; Kesari S; Farrell CJ; Curry WT; Zaupa C; Aghi M; Kuroda T; Stemmer-Rachamimov A; Shah K; Liu TC; Jeyaretna DS; Debasitis J; Pruszak J; Martuza RL; Rabkin SD
    Cancer Res; 2009 Apr; 69(8):3472-81. PubMed ID: 19351838
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Blockade of transforming growth factor-β signaling enhances oncolytic herpes simplex virus efficacy in patient-derived recurrent glioblastoma models.
    Esaki S; Nigim F; Moon E; Luk S; Kiyokawa J; Curry W; Cahill DP; Chi AS; Iafrate AJ; Martuza RL; Rabkin SD; Wakimoto H
    Int J Cancer; 2017 Dec; 141(11):2348-2358. PubMed ID: 28801914
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pediatric medulloblastoma xenografts including molecular subgroup 3 and CD133+ and CD15+ cells are sensitive to killing by oncolytic herpes simplex viruses.
    Friedman GK; Moore BP; Nan L; Kelly VM; Etminan T; Langford CP; Xu H; Han X; Markert JM; Beierle EA; Gillespie GY
    Neuro Oncol; 2016 Feb; 18(2):227-35. PubMed ID: 26188016
    [TBL] [Abstract][Full Text] [Related]  

  • 8. oHSV-P10 reduces glioma stem cell enrichment after oncolytic HSV therapy.
    Sahu U; Mullarkey MP; Pei G; Zhao Z; Hong B; Kaur B
    Mol Ther Oncolytics; 2023 Jun; 29():30-41. PubMed ID: 37114074
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Assessment of oncolytic HSV efficacy following increased entry-receptor expression in malignant peripheral nerve sheath tumor cell lines.
    Jackson JD; McMorris AM; Roth JC; Coleman JM; Whitley RJ; Gillespie GY; Carroll SL; Markert JM; Cassady KA
    Gene Ther; 2014 Nov; 21(11):984-90. PubMed ID: 25119379
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The complex relationship between integrins and oncolytic herpes Simplex Virus 1 in high-grade glioma therapeutics.
    Rivera-Caraballo KA; Nair M; Lee TJ; Kaur B; Yoo JY
    Mol Ther Oncolytics; 2022 Sep; 26():63-75. PubMed ID: 35795093
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Glioblastoma infiltration of both tumor- and virus-antigen specific cytotoxic T cells correlates with experimental virotherapy responses.
    Alayo QA; Ito H; Passaro C; Zdioruk M; Mahmoud AB; Grauwet K; Zhang X; Lawler SE; Reardon DA; Goins WF; Fernandez S; Chiocca EA; Nakashima H
    Sci Rep; 2020 Mar; 10(1):5095. PubMed ID: 32198420
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Oncolytic herpes simplex virus infects myeloma cells
    Ghose J; Dona A; Murtadha M; Gunes EG; Caserta E; Yoo JY; Russell L; Jaime-Ramirez AC; Barwick BG; Gupta VA; Sanchez JF; Sborov DW; Rosen ST; Krishnan A; Boise LH; Kaur B; Hofmeister CC; Pichiorri F
    Mol Ther Oncolytics; 2021 Mar; 20():519-531. PubMed ID: 33738338
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Stem cells loaded with multimechanistic oncolytic herpes simplex virus variants for brain tumor therapy.
    Duebgen M; Martinez-Quintanilla J; Tamura K; Hingtgen S; Redjal N; Wakimoto H; Shah K
    J Natl Cancer Inst; 2014 Jun; 106(6):dju090. PubMed ID: 24838834
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pediatric glioma stem cells: biologic strategies for oncolytic HSV virotherapy.
    Friedman GK; Raborn J; Kelly VM; Cassady KA; Markert JM; Gillespie GY
    Front Oncol; 2013; 3():28. PubMed ID: 23450706
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Oncolytic herpes simplex virus-based strategies: toward a breakthrough in glioblastoma therapy.
    Ning J; Wakimoto H
    Front Microbiol; 2014; 5():303. PubMed ID: 24999342
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The Impact of Macrophage- and Microglia-Secreted TNFα on Oncolytic HSV-1 Therapy in the Glioblastoma Tumor Microenvironment.
    Meisen WH; Wohleb ES; Jaime-Ramirez AC; Bolyard C; Yoo JY; Russell L; Hardcastle J; Dubin S; Muili K; Yu J; Caligiuri M; Godbout J; Kaur B
    Clin Cancer Res; 2015 Jul; 21(14):3274-85. PubMed ID: 25829396
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A novel oncolytic herpes simplex virus that synergizes with phosphoinositide 3-kinase/Akt pathway inhibitors to target glioblastoma stem cells.
    Kanai R; Wakimoto H; Martuza RL; Rabkin SD
    Clin Cancer Res; 2011 Jun; 17(11):3686-96. PubMed ID: 21505062
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Rad51 Degradation: Role in Oncolytic Virus-Poly(ADP-Ribose) Polymerase Inhibitor Combination Therapy in Glioblastoma.
    Ning J; Wakimoto H; Peters C; Martuza RL; Rabkin SD
    J Natl Cancer Inst; 2017 Mar; 109(3):1-13. PubMed ID: 28376211
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Enhanced antitumor efficacy of low-dose Etoposide with oncolytic herpes simplex virus in human glioblastoma stem cell xenografts.
    Cheema TA; Kanai R; Kim GW; Wakimoto H; Passer B; Rabkin SD; Martuza RL
    Clin Cancer Res; 2011 Dec; 17(23):7383-93. PubMed ID: 21976549
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Multimechanistic tumor targeted oncolytic virus overcomes resistance in brain tumors.
    Tamura K; Wakimoto H; Agarwal AS; Rabkin SD; Bhere D; Martuza RL; Kuroda T; Kasmieh R; Shah K
    Mol Ther; 2013 Jan; 21(1):68-77. PubMed ID: 22929661
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.